The discovery of antipsychotic agents in the 1950s revolutionized the
treatment of schizophrenia. A large body of evidence supports the dopa
mine D-2 receptor antagonist's efficacy in the treatment of psychotic
symptoms. However, the advent of newer agents seems to point to a more
complex interaction of neurotransmission in the pathophysiology of sc
hizophrenia. In fact, a defining characteristic of atypical agents is
a higher ratio of serotonin (5HT(2)) receptor blockade to D-2 receptor
blockade. Clozapine was the first atypical agent to be introduced; it
was followed by risperidone, olanzapine, and now quetiapine, which is
a dibenzothiazepine derivative structurally related to clozapine and
olanzapine.